Cefixime
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00671 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | gonococcal urethritis | KG + DL |
| 2 | Ureaplasma urethritis | KG + DL |
| 3 | uterine inflammatory disease | KG + DL |
| 4 | xanthogranulomatous pyelonephritis | KG + DL |
| 5 | laryngitis | KG + DL |
| 6 | epiglottitis | KG + DL |
| 7 | laryngotracheitis | KG + DL |
| 8 | urogenital tuberculosis | KG + DL |
| 9 | tracheal disease | KG + DL |
| 10 | hyperamylasemia | KG + DL |
| 11 | polyclonal hyperviscosity syndrome | KG + DL |
| 12 | congenital analbuminemia | KG + DL |
| 13 | blood group incompatibility | KG + DL |
| 14 | heart neoplasm | KG + DL |
| 15 | premalignant hematological system disease | KG + DL |
| 16 | congenital anomaly of ventricular septum | KG + DL |
| 17 | malignant pleural mesothelioma | KG + DL |
| 18 | monoclonal gammopathy | KG + DL |
| 19 | malignant visceral pleura tumor | KG + DL |
| 20 | ulcerative proctosigmoiditis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.